NO20051040L - Anvendelse av alkylfosfokoliner i kombinasjon med antitumormedikamenter - Google Patents

Anvendelse av alkylfosfokoliner i kombinasjon med antitumormedikamenter

Info

Publication number
NO20051040L
NO20051040L NO20051040A NO20051040A NO20051040L NO 20051040 L NO20051040 L NO 20051040L NO 20051040 A NO20051040 A NO 20051040A NO 20051040 A NO20051040 A NO 20051040A NO 20051040 L NO20051040 L NO 20051040L
Authority
NO
Norway
Prior art keywords
alkylphosphocholines
combination
antitumor drugs
cytostatics
benign
Prior art date
Application number
NO20051040A
Other languages
English (en)
Other versions
NO335196B1 (no
Inventor
Juergen Engel
Eckhard Guenther
Herbert Sindermann
Original Assignee
Zentaris Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zentaris Gmbh filed Critical Zentaris Gmbh
Publication of NO20051040L publication Critical patent/NO20051040L/no
Publication of NO335196B1 publication Critical patent/NO335196B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Oppfinnelsen angår alkylfosfokoliner i kombinasjon med antitumormedikamenter for behandling av benigne og maligne tumorsykdommer hos mennesker og pattedyr. Alkylfosfokoliner kan anvendes i en i kombinasjon ifølge oppfinnelsen med en eller en kombinasjon av ulike godkjente cytostatika. Foretrukne alkylfosfokoliner er representert ved formel II.
NO20051040A 2002-07-30 2005-02-25 Anvendelse av alkylfosfokoliner i kombinasjon med antitumormedikamenter NO335196B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39961502P 2002-07-30 2002-07-30
PCT/EP2003/008346 WO2004012744A1 (de) 2002-07-30 2003-07-29 Anwendung von alkylphosphocholinen in kombination mit antitumormedikamenten

Publications (2)

Publication Number Publication Date
NO20051040L true NO20051040L (no) 2005-02-25
NO335196B1 NO335196B1 (no) 2014-10-20

Family

ID=31495746

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20051040A NO335196B1 (no) 2002-07-30 2005-02-25 Anvendelse av alkylfosfokoliner i kombinasjon med antitumormedikamenter

Country Status (26)

Country Link
US (3) US8389497B2 (no)
EP (2) EP2301551A1 (no)
JP (1) JP2005535688A (no)
KR (3) KR20110102485A (no)
CN (1) CN1302780C (no)
AR (1) AR040717A1 (no)
AT (1) ATE516036T1 (no)
AU (2) AU2003253350B2 (no)
BR (1) BR0313048A (no)
CA (1) CA2493023C (no)
CY (1) CY1111902T1 (no)
DK (1) DK1545553T3 (no)
ES (1) ES2369535T3 (no)
HR (1) HRP20050184B1 (no)
IL (1) IL166329A (no)
MX (1) MXPA05001203A (no)
NO (1) NO335196B1 (no)
NZ (1) NZ538428A (no)
PL (1) PL375493A1 (no)
PT (1) PT1545553E (no)
RU (1) RU2005105693A (no)
SI (1) SI1545553T1 (no)
TW (1) TWI332007B (no)
UA (1) UA82322C2 (no)
WO (1) WO2004012744A1 (no)
ZA (1) ZA200500453B (no)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8383605B2 (en) 2002-07-30 2013-02-26 Aeterna Zentaris Gmbh Use of alkylphosphocholines in combination with antimetabolites for the treatment of benign and malignant oncoses in humans and mammals
JP2005535688A (ja) 2002-07-30 2005-11-24 ツェンタリス ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗腫瘍医薬との組合せにおけるアルキルホスホコリンの使用
DE10324911B4 (de) 2003-05-30 2005-08-18 Siemens Ag Röntgenvorrichtung mit partiellem digitalem Detektor und Verfahren zum Betrieb einer solchen
WO2006081452A2 (en) * 2005-01-28 2006-08-03 Robert Birch Co-administration of perifosine with chemotherapeutics
EP1800684A1 (en) * 2005-12-20 2007-06-27 Zentaris GmbH Novel alkyl phospholipid derivatives and uses thereof
US20070167408A1 (en) * 2005-12-19 2007-07-19 Zentaris Gmbh Novel alkyl phospholipid derivatives with reduced cytotoxicity and uses thereof
EP1962862B1 (en) * 2005-12-19 2013-09-04 Æterna Zentaris GmbH Alkyl phospholipid derivatives with reduced cytotoxicity and uses therof
US8703179B2 (en) 2006-05-11 2014-04-22 Kimberly-Clark Worldwide, Inc. Mucosal formulation
KR20140098185A (ko) * 2007-07-30 2014-08-07 아디아 바이오사이언스즈 인크. 다형체를 포함하는, ｍｅｋ의 억제제로서의 ｎ-(아릴아미노) 술폰아미드의 유도체 및 조성물, 사용 방법 및 이의 제조 방법
NZ593343A (en) * 2008-12-11 2013-04-26 Abraxis Bioscience Llc Combination cancer treatment conprising Abraxane and an inflamatory inhibitor
MX2011011596A (es) 2010-03-31 2012-02-01 Keryx Biopharmaceuticals Inc Perifosina y capecitabina como un tratamiento combinado para cancer.

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5942639A (en) * 1991-07-04 1999-08-24 Asta Medica Aktiengesellschaft Process for the preparation of alkylphosphocholines and the production thereof in pure form
ATE136783T1 (de) * 1991-07-04 1996-05-15 Asta Medica Ag Arzneimittel mit antineoplastischer wirkung enthaltend als wirkstoff octadecyl-(2-(n- methylpiperidino)-ethyl>-phosphat und verfahren zu dessen herstellung
US6172050B1 (en) * 1992-07-11 2001-01-09 Asta Medica Aktiengesellschaft Phospholipid derivatives
JP3079993B2 (ja) * 1996-03-27 2000-08-21 日本電気株式会社 真空マイクロデバイスおよびその製造方法
DE19650778C2 (de) * 1996-12-06 2001-01-04 Asta Medica Ag Verwendung von Dopaminrezeptor-Antagonisten in der palliativen Tumortherapie
ES2175663T3 (es) * 1998-01-22 2002-11-16 Zentaris Ag Composiciones farmaceuticas solidas que contienen miltefosina para administracion oral en el tratamiento de la leshmaniasis.
ATE226843T1 (de) * 1998-12-04 2002-11-15 Max Delbrueck Centrum Mittel zur tumortherapie auf liposomenbasis, die tamoxifen enthalten
US6583127B1 (en) 1998-12-21 2003-06-24 Inkeysa. Sa Use of etherlysophospholipids as antiinflammatory agents
LT2762140T (lt) * 2001-02-19 2017-06-26 Novartis Ag Solidinių smegenų navikų gydymas rapamicino dariniu
KR20040018341A (ko) * 2001-03-23 2004-03-03 샤이어 바이오켐 인코포레이티드 암치료용 약제 조성물
WO2003005522A1 (es) 2001-07-04 2003-01-16 Acuna Arturo Tapones para sellado de ductos para redes electricas, telefonicas y de fibra optica.
ES2263835T3 (es) * 2002-01-02 2006-12-16 Nerviano Medical Sciences S.R.L. Terapia combinada contra tumores que comprende derivados de distamicina acriloil sustituidos e inhibidores proteina quinasa (serina/treonina quinasa).
JP2005535688A (ja) 2002-07-30 2005-11-24 ツェンタリス ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗腫瘍医薬との組合せにおけるアルキルホスホコリンの使用
WO2005000318A2 (en) * 2003-06-23 2005-01-06 Neopharm, Inc. Method of inducing apoptosis and inhibiting cardiolipin synthesis
WO2006081452A2 (en) 2005-01-28 2006-08-03 Robert Birch Co-administration of perifosine with chemotherapeutics
US20070167408A1 (en) 2005-12-19 2007-07-19 Zentaris Gmbh Novel alkyl phospholipid derivatives with reduced cytotoxicity and uses thereof
MX2011011596A (es) 2010-03-31 2012-02-01 Keryx Biopharmaceuticals Inc Perifosina y capecitabina como un tratamiento combinado para cancer.

Also Published As

Publication number Publication date
KR20130016413A (ko) 2013-02-14
HK1080751A1 (en) 2006-05-04
CA2493023A1 (en) 2004-02-12
US20040097470A1 (en) 2004-05-20
AU2008203060B2 (en) 2011-04-21
EP2301551A1 (de) 2011-03-30
KR20050026028A (ko) 2005-03-14
DK1545553T3 (da) 2011-09-12
SI1545553T1 (sl) 2011-09-30
KR20110102485A (ko) 2011-09-16
KR101066804B1 (ko) 2011-09-22
AU2003253350B2 (en) 2008-06-26
AU2008203060A1 (en) 2008-07-31
ES2369535T3 (es) 2011-12-01
EP1545553A1 (de) 2005-06-29
NO335196B1 (no) 2014-10-20
CY1111902T1 (el) 2015-11-04
AR040717A1 (es) 2005-04-20
NZ538428A (en) 2006-09-29
PT1545553E (pt) 2011-09-12
WO2004012744A1 (de) 2004-02-12
TWI332007B (en) 2010-10-21
US20100190738A1 (en) 2010-07-29
TW200404073A (en) 2004-03-16
JP2005535688A (ja) 2005-11-24
US8507710B2 (en) 2013-08-13
IL166329A0 (en) 2006-01-15
EP1545553B1 (de) 2011-07-13
HRP20050184B1 (hr) 2014-04-11
US20100189784A1 (en) 2010-07-29
ZA200500453B (en) 2005-08-31
US8551977B2 (en) 2013-10-08
US8389497B2 (en) 2013-03-05
AU2003253350A1 (en) 2004-02-23
PL375493A1 (en) 2005-11-28
CN1302780C (zh) 2007-03-07
CN1671397A (zh) 2005-09-21
UA82322C2 (uk) 2008-04-10
HRP20050184A2 (en) 2005-04-30
RU2005105693A (ru) 2005-07-10
IL166329A (en) 2012-08-30
ATE516036T1 (de) 2011-07-15
CA2493023C (en) 2012-01-31
BR0313048A (pt) 2005-06-14
MXPA05001203A (es) 2005-06-08

Similar Documents

Publication Publication Date Title
MY155218A (en) Small molecules useful in the treatment of inflammatory disease
ES2391382T8 (es) Compuestos de aril-urea en combinación con otros agentes citostáticos o citotóxicos para tratamiento de cánceres humanos
YU21401A (sh) Tetrahidropiridoetri
ATE448232T1 (de) Substituierte heterozyklen
NO20071426L (no) Kreft kombinasjonsbehandling omfattende AZD2171 og Imatinib
DE50310516D1 (de) Fredericamycin-derivate
MXPA05009595A (es) Compuestos 7-amino-isoindolilo y sus usos farmaceuticos.
UA85559C2 (en) Aminobenzophenone compounds
ATE442142T1 (de) Fredericamycin-derivate als arzneimittel zur tumorbehandlung
BRPI0415525A (pt) derivados de imidazola e seu uso como agentes farmacêuticos
CY1111902T1 (el) Χρηση ακυλοφωσφοχολινων σε συνδυασμο με αντινεοπλασματικα φαρμακα
PT1390371E (pt) Oxazolo- e furopirimidinas e sua utilizacao em medicamentos contra tumores
ATE311389T1 (de) Wirkstoffvorläufer von imidazopyridin-derivaten
SE0302304D0 (sv) Novel compounds
SE0300456D0 (sv) Novel compounds
NZ524936A (en) Methods of inducing cancer cell death and tumor regression using a FTP inhibitor and a tyrosine kinase inhibitor
DK1558620T3 (da) Rutheniumkomplekser med anticancervirkning
DE60131968D1 (de) PYRANOÄ2,3-cÜIMIDAZOÄ1,2-aÜPYRIDIN-DERIVATE ZUR BEHANDLUNG VON GASTROINTESTINALEN ERKRANKUNGEN
PT1606233E (pt) Derivados de esteres lipidicos de nucleotidos
TW200504051A (en) Novel acridine derivatives and their use as medicaments
BRPI0415355A (pt) triarilimidazóis
WO2002074735A3 (de) Biurethanderivate
FR2877667B1 (fr) Derives de 4,7-dioxobenzothiazole-2-carboxamides, leur preparation et leurs applications therapeutiques
ATE397003T1 (de) Ruthenium(ii)-komplexe zur behandlung von tumoren
ATE423780T1 (de) Makrozyclen zur behandlung von krebserkrankungen

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees